clinical trial · NCT07222137
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Eli Lilly and Company·phase3·recruiting·n = 150
Diabetes Mellitus, Type 1BaricitinibPlacebo
brief summary
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
started
Jan 12, 2026
primary completion
Jul 1, 2031
completion
Jul 1, 2031
last updated
Apr 17, 2026
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol